SRPT news · SRPT stock

KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak

Yahoo Finance · Aug 24, 2026 · Sarepta Therapeutics Inc (SRPT)

Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.

Original at Yahoo Finance

Not investment advice. Cached headline, not a full reprint.